Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

Centre Hospitalier Universitaire de Saint Etienne1 site in 1 country8 target enrollmentJune 5, 2023

ConditionsEndophthalmitis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Endophthalmitis
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Enrollment: 8
Locations: 1
Primary Endpoint: Visual acuity
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.

Registry

clinicaltrials.gov

Start Date

June 5, 2023

End Date

June 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient who had endophtalmitis following an OZURDEX implant injection within 2 months

Exclusion Criteria

•Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis

Outcomes

Primary Outcomes

Visual acuity

Time Frame: 2018 to 2023

Evolution of visual acuity from the first to the last patient includes

Secondary Outcomes

Tomography(2018 to 2023)
IOP measured in mmHg by tonometer and confirmed with Goldman Applanation(2018 to 2023)
Resumption of intravitreal therapy(2018 to 2023)